# Radioligand Therapy RLT Market

> Radioligand Therapy (RLT) Market Size, Growth Research Report By Isotope (Fluorine – 18, Gallium – 68, Lutetium – 177, and Others), By Targeted Receptor (Prostate-specific Membrane Antigen (PSMA), Somatostatin Receptor (SSTR), Epidermal Growth Factor Receptor (EGFR), and Others), By Indication (Prostate Cancer, Neuroendocrine Tumors (NETs), Breast Cancer, and Others), By End User (Hospitals & Clinics, Diagnostic Centers, and Others), and By Region (North America, Europe, Asia-Pacific, and Rest of the World) - Competitor Industry Analysis and Trends Forecast Till 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 10.94%
- **2025:** USD 5.29 Billion
- **2035:** USD 14.94 Billion
- **Key Players:** Novartis AG, Bayer AG, Lantheus Holdings, Curium, Telix Pharmaceuticals, ITM Isotope Technologies Munich SE, Bristol Myers Squibb (RayzeBio), AstraZeneca (Fusion Pharmaceuticals)

**Report ID:** MRFR/Pharma/10303-HCR · **Pages:** 128 · **Author:** Rahul Gotadki & Nidhi Mandole · **Last Updated:** October 22, 2026

**URL:** https://www.marketresearchfuture.com/reports/radioligand-therapy-rlt-market-11824

---

## Market Summary

The Global Radioligand Therapy (RLT) Market size was valued at USD 8.14 Billion in 2024, and the market is projected to grow from USD 8.906 Billion in 2025 to USD 21.89 Billion by 2035, registering a CAGR of 9.41% during the forecast period 2025–2035. North America led the market in 2024 with over 45.45% share, generating around USD 3.7 Billion in revenue.
 
The increasing adoption of precision oncology is a major growth factor for the Radioligand Therapy (RLT) Market. RLT enables targeted delivery of radiation directly to cancer cells while minimizing damage to healthy tissues, improving treatment efficacy and supporting its expanding use across prostate cancer and neuroendocrine tumor management.
 
According to the World Health Organization (WHO), cancer caused approximately 9.7 million deaths globally in 2022, with an estimated 20 million new cancer cases, highlighting the growing need for advanced targeted therapies such as radioligand treatment and strengthening long-term market demand.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Label expansion of PSMA-targeted therapy into earlier prostate cancer lines | +2.4% | North America, Europe, Japan | Medium-term (2–4 yr) | [3][4] |
| Large-cap pharma acquisitions and pipeline funding | +1.9% | North America, Europe | Medium-term (2–4 yr) | [8][10][11] |
| Rising global burden of prostate cancer and neuroendocrine tumors | +1.6% | Global | Long-term (≥4 yr) | [7] |
| First-line and pediatric expansion of SSTR-targeted therapy | +1.5% | Global | Short-term (≤2 yr) | [5][19] |
| Isotope and radioligand manufacturing capacity build-out | +1.3% | North America, Europe | Short-term (≤2 yr) | [12][17] |
| Reimbursement reform for companion diagnostic imaging | +1.1% | North America | Short-term (≤2 yr) | [13] |

### Label Expansion of PSMA-Targeted Therapy

VISION established the clinical case, with Lu-177 PSMA-617 cutting the risk of death by 38% versus standard care in post-taxane metastatic castration-resistant prostate cancer [4]. PSMAfore then reported median radiographic progression-free survival of 12.0 months against 5.6 months for an androgen-receptor pathway switch in taxane-naïve patients [3], supporting the FDA's March 2025 label expansion . Each earlier line adds patients who are fitter, stay on therapy longer and complete more cycles, lifting revenue per treated patient.

### Large-Cap Pharma Acquisitions

Strategic capital has flooded into the field. Bristol Myers Squibb paid USD 4.1 billion for RayzeBio [8], AstraZeneca acquired Fusion Pharmaceuticals for up to USD 2.4 billion , Eli Lilly closed its USD 1.4 billion POINT Biopharma deal [10], and Novartis committed USD 1 billion upfront for Mariana Oncology [11]. These buyers bring global trial networks and payer access that small developers lacked, compressing the path from Phase 2 data to multi-country launch for actinium-225 and lead-212 candidates.

### Rising Disease Burden

GLOBOCAN recorded 1.47 million new prostate cancer cases worldwide in 2022 , and the Lancet Commission on prostate cancer projects annual cases reaching 2.9 million by 2040 as populations age [7]. Neuroendocrine tumor incidence is also climbing, partly because wider cross-sectional imaging detects disease earlier. A larger diagnosed pool feeds directly into the eligible population for PSMA- and SSTR-targeted agents, particularly in aging markets such as Japan, Germany and Italy.

### First-Line and Pediatric Expansion of SSTR-Targeted Therapy

NETTER-1 first demonstrated a 79% reduction in the risk of progression or death with Lu-177 dotatate in midgut neuroendocrine tumors [19]. NETTER-2 pushed the therapy into first-line use, reporting median progression-free survival of 22.8 months versus 8.5 months for high-dose octreotide in higher-grade GEP-NETs [5]. The FDA's April 2024 approval for patients aged 12 and older  widened the label further, giving SSTR therapy a longer treatment runway per patient.

### Manufacturing Capacity Build-Out

Supply, not demand, has repeatedly capped volumes. Novartis runs dedicated radioligand sites in Indianapolis, Millburn, Ivrea and Zaragoza and has earmarked further U.S. facilities within its USD 23 billion domestic investment program [12]. The U.S. DOE Isotope Program is scaling accelerator-based actinium-225 production with national laboratory partners [17]. Each new site shortens the delivery radius for short-lived isotopes, letting treatment centers farther from original production hubs schedule reliably.

### Reimbursement Reform for Companion Imaging

Diagnostic PET agents used to select patients were historically bundled into hospital outpatient payments, discouraging use. Under the CY 2025 Outpatient Prospective Payment System final rule, CMS began paying separately for diagnostic radiopharmaceuticals with per-day costs above USD 630 [13]. Hospitals can now order PSMA and SSTR PET scans without absorbing the agent cost, removing friction at the patient-identification step and lifting referral volumes into therapy.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Isotope supply fragility and short shelf life | −1.4% | Global | Medium-term (2–4 yr) | [1][16] |
| High per-dose cost and uneven health technology assessment outcomes | −1.2% | Europe, Asia-Pacific | Medium-term (2–4 yr) | [18] |
| Shortage of trained nuclear medicine staff and certified sites | −0.9% | Global | Long-term (≥4 yr) | [15] |
| Price erosion from generic Lu-177 dotatate | −0.7% | North America, Europe | Medium-term (2–4 yr) | [22] |
| Radioactive waste handling and long-lived impurities | −0.6% | Europe, Middle East and Africa | Long-term (≥4 yr) | [16] |

### Isotope Supply Fragility

Lu-177 has a half-life of about 6.7 days, so doses cannot be stockpiled and any plant disruption reaches patients within a week. In May 2022, Novartis temporarily suspended Pluvicto and Lutathera production at its Ivrea and Millburn sites over potential quality issues, delaying treatment across the United States and Europe [1]. Precursor supply also depends on a small fleet of ageing research reactors, a concentration risk the OECD Nuclear Energy Agency continues to flag [16].

### High Cost and Uneven HTA Outcomes

Pluvicto launched in the United States at a list price near USD 42,500 per dose, putting a full six-cycle course above USD 250,000. England's NICE declined to recommend routine use in its 2023 appraisal on cost-effectiveness grounds [18], and similar scrutiny slows uptake in single-payer systems across Europe and Asia-Pacific. Until value-based contracts or lower-cost generics reach scale, access outside North America will lag clinical eligibility.

### Workforce and Certified Site Shortage

Every treating center needs an authorized-user physician, a radiation safety officer, a nuclear pharmacist and shielded infusion space. The IAEA's IMAGINE database shows wide gaps in nuclear medicine capacity, with many low- and middle-income countries operating fewer than one [PET scanner](https://www.marketresearchfuture.com/reports/pet-scanner-market-29439) per million people [15]. Training pipelines take years to fill, so staffing rather than capital becomes the binding constraint on adding new treatment sites.

### Generic Price Erosion

Lu-177 dotatate is losing exclusivity. Lantheus is advancing PNT2003, a radioequivalent of Lutathera, and has disclosed its regulatory pathway in annual filings [22]. Hospitals and group purchasing organizations will use generic entry to renegotiate pricing, compressing per-dose revenue in the SSTR segment even as treated volumes rise. Originators are responding with next-generation SSTR antagonists and alpha-emitter candidates to defend share.

### Radioactive Waste Handling

Carrier-added Lu-177 contains the metastable impurity Lu-177m, with a half-life of about 160 days, forcing long decay-in-storage periods for contaminated waste [16]. Facilities in parts of Europe and the Middle East face tight disposal rules that raise operating costs. Actinium-225 adds daughter-isotope tracking requirements. Smaller hospitals often decline to start programs once they price shielded storage and waste logistics.

## Opportunities

## Radioligand Therapy RLT Market Opportunities

### Alpha-Emitter Next-Generation Payloads

Actinium-225 and lead-212 conjugates deliver higher-energy, shorter-range radiation that can treat patients who progress after Lu-177 therapy. Novartis's Mariana acquisition [11], AstraZeneca's Fusion deal  and Sanofi's AlphaMedix license [20] all target this space. Sequencing a beta agent followed by an alpha agent could double the treatment lines available per patient, raising lifetime revenue in prostate cancer and neuroendocrine tumors.

### Emerging Markets in Asia-Pacific and the Middle East

The Asia-Pacific region bears over 50% of global cancer incidence (over 10.4 million new cases annually per WHO/IARC GLOBOCAN data). However, treatment access remains uneven. IAEA IMAGINE data show global average PET availability at just 0.77 scanners per million people, with low-income regions falling below 0.1 per million. China’s NMPA priority reviews and Gulf State infrastructure investments offer entry points for localized manufacturing and regional distribution partnerships.

### Distributed Radiopharmacy and Dose-as-a-Service Models

Centralized manufacturing struggles with short half-lives. A hub-and-spoke model, in which regional radiopharmacies label ligands with locally supplied isotope, cuts delivery time and waste. Lantheus's acquisition of Evergreen Theragnostics [22] signals interest in contract manufacturing as a standalone revenue line. Dose-as-a-service contracts that bundle isotope, labeling, delivery and waste return can open hospitals that lack in-house radiopharmacy staff.

### Monetizing Dosimetry and Real-World Data

Post-therapy SPECT imaging generates patient-level dosimetry that most centers discard. Aggregated, this data can support personalized activity dosing, label expansions and outcomes-based contracts with payers. Software vendors and manufacturers that build dosimetry platforms can license analytics to hospitals and sell de-identified datasets to pipeline developers, creating recurring revenue that does not depend on dose volume.

### FAP and Pan-Tumor Targets

Fibroblast Activation Protein (FAP) is overexpressed in cancer-associated fibroblasts across more than 90% of epithelial tumors, including pancreatic, breast, and lung carcinomas. Next-generation FAP inhibitors engineered with albumin binders extend tumor retention times in Phase 1/2 trials. Broad pan-tumor expression unlocks a vast patient market, as WHO reports over 20 million new global cancer cases annually, significantly expanding radioligand therapy beyond traditional PSMA and SSTR2 targets.

## Future Outlook

## Radioligand Therapy RLT Market Future Outlook

### Alpha Emitters Become the Second Commercial Wave

By the early 2030s, the Radioligand Therapy (RLT) Market is expected to run on two payload classes. Actinium-225 PSMA agents such as Novartis's AAA817 and lead-212 SSTR agents from Sanofi's partnership [20] are designed for patients progressing after Lu-177 treatment. IARC projects global cancer cases rising from 20 million in 2022 to 35 million by 2050 , a demand base large enough to support multiple payloads per indication.

### Isotope Supply Chain Diversification

Supply security will define competitive advantage. The OECD Nuclear Energy Agency continues to monitor reactor ageing risk for medical isotope supply [16], and the European Commission's SAMIRA plan commits funding to secure production chains [23]. Accelerator and cyclotron routes for actinium-225 and lead-212, backed by the U.S. DOE Isotope Program [17], should reduce dependence on a handful of research reactors after 2028.

### AI-Driven Dosimetry and Patient Selection

Fixed-activity dosing remains standard, but personalized dosimetry is gaining ground. AI tools that segment PSMA PET scans and calculate absorbed tumor dose can predict response and flag kidney or salivary gland toxicity before each cycle. As these tools gain regulatory clearance, they will support adaptive dosing of each lutetium-177 radioligand cycle and generate the outcomes data payers want for value-based contracts.

### Decentralized Treatment Networks

Treatment will migrate from academic centers toward community settings. Specialized nuclear medicine centers and hospital networks are adopting standardized protocols, and regional radiopharmacies shorten dose delivery windows. By 2035, a larger share of cycles should be administered close to patients' homes, reducing travel burden for an older patient population [7].

## Segment Insights

## Radioligand Therapy RLT Market Segmentation

Market Research Future segments the Radioligand Therapy (RLT) Market by target, indication and end user. Each table discloses one metric per segment.

### By Target

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Prostate-Specific Membrane Antigen | 55.5% share | Pluvicto's earlier-line labels and PSMA PET availability |
| Somatostatin Receptor | USD 1.69 Billion | First-line and pediatric Lu-177 dotatate use in GEP-NETs |
| Fibroblast Activation Protein | 19.8% CAGR | Pan-tumor stromal expression and improved tumor retention |
| Gastrin-Releasing Peptide Receptor | 2.1% share | PSMA-low prostate and breast cancers |
| Other Targets | USD 0.21 Billion | CAIX, CXCR4 and other early-stage antigens |

Within the Radioligand Therapy (RLT) Market, prostate-specific membrane antigen remains the commercial anchor because Pluvicto's labels and widespread PSMA PET capacity make patient selection routine. Somatostatin receptor agents form the second pillar, with expanded GEP-NET indications sustaining demand. Fibroblast activation protein is the fastest-growing target from a small base; ligands from Novartis, Eli Lilly and Telix are designed to fix the short tumor retention that held earlier compounds back.

### By Indication

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Prostate Cancer | 52.4% share | Earlier-line PSMA therapy and rising incidence |
| Gastroenteropancreatic Neuroendocrine Tumors | 17.3% CAGR | NETTER-2 first-line data and lower-cost generics |
| Small Cell Lung Cancer | 1.6% share | SSTR2-targeted actinium-225 Phase 3 programs |
| Hepatocellular Carcinoma | USD 0.07 Billion | Glypican-3 and FAP ligands in early trials |
| Breast Cancer | 16.1% CAGR | GRPR and FAP strategies for hormone-positive disease |
| Other Indications | USD 0.28 Billion | Renal, pancreatic and thyroid cancer programs |

Prostate cancer leads the Radioligand Therapy (RLT) Market by indication, reflecting Pluvicto's scale and the large post-androgen-receptor-inhibitor population. Gastroenteropancreatic neuroendocrine tumors are growing fastest as first-line Lu-177 dotatate use spreads and generic entry lowers per-cycle cost. Small cell lung cancer, hepatocellular carcinoma and breast cancer represent the next frontier, with SSTR2, FAP and GRPR programs moving through clinical development.

### By End User

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Tertiary Care Academic and Comprehensive Cancer Centers | 55.2% share | Multidisciplinary teams, trial access and on-site radiopharmacy |
| Specialized Nuclear Medicine Centers | 13.5% CAGR | Accreditation programs and standardized protocols |
| Hospitals | USD 0.98 Billion | Integration with community oncology services |
| Specialized Clinics | 7.3% share | Private theranostic clinics in urban markets |
| Other End Users | USD 0.11 Billion | Research institutes and trial sites |

Tertiary care academic and comprehensive cancer centers hold the largest share of the Radioligand Therapy (RLT) Market because they combine nuclear medicine, oncology and radiation safety expertise under one roof. Specialized nuclear medicine centers are expanding fastest as accreditation and standardized administration protocols lower barriers to entry. Hospitals form a large secondary channel, though trained staff rather than equipment limits how quickly they add capacity.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 46.8% share | Earlier-line PSMA therapy, U.S. isotope capacity, CMS imaging payment |
| Europe | USD 1.61 Billion | Isotope security under SAMIRA, PRRT expertise, HTA-driven pricing |
| Asia-Pacific | 14.6% CAGR | Approvals in Japan and China, cyclotron build-out, private oncology chains in India |
| South America | 3.4% share | Brazil's nuclear medicine network, import-dependent isotope supply |
| Middle East and Africa | USD 0.17 Billion | Gulf comprehensive cancer centers, theranostic suites, South African reactor supply |
| Total | USD 5.29 Billion | — |

North America anchors the Radioligand Therapy (RLT) Market, while Asia-Pacific supplies the fastest incremental growth. Europe benefits from long PRRT experience, and South America and the Middle East and Africa remain early-stage but investable as theranostic centers open.

### North America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| US | 88.6% of regional share | Pre-taxane Pluvicto label, Medicare coverage, dense PSMA PET network |
| Canada | USD 0.19 Billion | Provincial reimbursement and domestic isotope production |
| Mexico | 15.2% CAGR | Private oncology centers adding PSMA PET and therapy |

The United States accounts for the bulk of the Radioligand Therapy (RLT) Market in North America, driven by Pluvicto's pre-taxane label, Medicare coverage and a dense network of PSMA PET sites [13]. Production in Indiana and New Jersey, plus planned new facilities, reduces delivery times [12]. Canada leverages isotope production from McMaster University's reactor and TRIUMF, while Mexico's growth depends on private hospital groups in Mexico City and Monterrey adopting theranostics.

### Europe

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Germany | 24.8% of regional share | University PRRT and PSMA therapy centers |
| UK | USD 0.25 Billion | NHS cancer center capacity, constrained by HTA outcomes |
| France | 12.1% CAGR | National reimbursement of Lu-177 agents |
| Italy | 12.6% of regional share | Domestic production site at Ivrea |
| Spain | USD 0.11 Billion | Zaragoza radioligand manufacturing hub |
| Nordic Countries | 12.8% CAGR | Centralized cancer care and early theranostic adoption |
| Russia | 4.1% of regional share | Domestic reactor isotope supply |
| Rest of Europe | USD 0.18 Billion | Cross-border referrals to established centers |

Germany leads European volumes thanks to university hospitals in Bad Berka, Munich and Essen that pioneered PRRT and PSMA therapy. The SAMIRA action plan backs reactor refurbishment, and Lu-177 supply security across the bloc [23], while EMA approval offers a single regulatory entry point. NICE's restrictive appraisal slows UK uptake [18], and Italy hosts the Ivrea production site. Russia relies on domestic reactor isotopes under separate regulatory channels.

### Asia-Pacific

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| China | 26.4% of regional share | NMPA accelerated review and domestic Lu-177 production |
| India | 18.4% CAGR | Private cancer hospital chains adding theranostic units |
| Japan | USD 0.31 Billion | PMDA approval of Lutathera and aging population |
| South Korea | 9.6% of regional share | Tertiary hospital nuclear medicine depth |
| ASEAN | 16.9% CAGR | National cancer centers launching Lu-177 programs |
| Rest of Asia-Pacific | USD 0.07 Billion | Australian and regional theranostic expertise |

Japan is the largest national contributor to the Radioligand Therapy (RLT) Market in Asia-Pacific, supported by PMDA approval of Lutathera in 2021 and a rapidly aging population. China's NMPA has accelerated review of imported radioligands while domestic companies scale Lu-177 production, and India's private cancer hospital chains are adding theranostic units quickly. ASEAN growth centers on Singapore, Thailand and Malaysia, where national cancer centers have started Lu-177 programs.

### South America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Brazil | 58.2% of regional share | IPEN isotope production and private oncology networks |
| Argentina | USD 0.03 Billion | RA-10 reactor project for isotope self-sufficiency |
| Rest of South America | 11.4% CAGR | Imported doses for capital-city cancer centers |

Brazil dominates regional demand, with IPEN in São Paulo producing radioisotopes and private hospitals offering PSMA therapy. ANVISA registration of Lu-177 agents has improved access, though most patients still pay privately or through supplementary insurance. Argentina benefits from the RA-10 multipurpose reactor project [16], designed to support regional isotope self-sufficiency.

### Middle East and Africa

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 27.5% of regional share | Vision 2030 health investment and in-house cyclotrons |
| UAE | 16.3% CAGR | New theranostic suites in Abu Dhabi and Dubai |
| South Africa | USD 0.03 Billion | SAFARI-1 reactor isotope supply |
| Egypt | 9.8% of regional share | Public hospital procurement budgets |
| Rest of MEA | 11.2% CAGR | Referral flows to Gulf centers |

Saudi Arabia leads the region as King Faisal Specialist Hospital and Research Centre expands its cyclotron and theranostic program under Vision 2030 health investment. The UAE is adding PSMA therapy at cancer centers in Abu Dhabi and Dubai. South Africa's SAFARI-1 reactor supplies isotopes regionally and supports local PRRT expertise, while Egypt's growth depends on public hospital procurement budgets [15].

## Competitive Benchmarking

## Competitive Benchmarking

The Radioligand Therapy (RLT) Market is commercially concentrated but scientifically fragmented. Novartis controls the two leading approved products, pushing the estimated Herfindahl-Hirschman Index near 3,000 and the top-five share to roughly 66–76%. Below that tier, more than 50 companies run clinical programs, and big-pharma entrants are using acquisitions to compete on alpha emitters and new targets rather than head-to-head with Lu-177 PSMA.

| Company | Est. Revenue Share Range | Key Offerings for Radioligand Therapy (RLT) Market | Strategic Positioning |
| --- | --- | --- | --- |
| Novartis AG | ~52–58% | Pluvicto, Lutathera, Locametz imaging kit, AAA817 actinium-225 PSMA | Category leader with owned isotope and radioligand manufacturing on three continents |
| Bayer AG | ~6–9% | Xofigo (radium-223), actinium-225 PSMA programs | Bone-metastasis franchise extending into targeted alpha therapy |
| Lantheus Holdings | ~3–5% | PNT2003 Lu-177 dotatate radioequivalent, Pylarify PSMA PET agent | Diagnostic leader building therapy and contract manufacturing via Evergreen |
| Curium | ~2–4% | Lu-177 PSMA-I&T (ECLIPSE Phase 3), non-carrier-added Lu-177 supply | Vertically integrated isotope producer serving third-party developers |
| Telix Pharmaceuticals | ~1–3% | Illuccix PSMA PET kit, TLX591 Lu-177 rosopatamab, TLX250 renal program | Theranostic pairing linking imaging revenue to therapy pipeline |
| ITM Isotope Technologies Munich SE | ~1–2% | ITM-11 (n.c.a. Lu-177 edotreotide), EndolucinBeta Lu-177 supply | Isotope supplier advancing its own SSTR therapy |
| Bristol Myers Squibb (RayzeBio) | ~0–1% | RYZ101 actinium-225 SSTR agent, Indianapolis manufacturing | Actinium-first strategy in GEP-NETs and SCLC |
| Eli Lilly and Company (POINT Biopharma) | ~0–1% | PNT2002 Lu-177 PSMA, FAP-targeted candidates | Pipeline breadth backed by in-house radioligand production |
| AstraZeneca (Fusion Pharmaceuticals) | ~0–1% | FPI-2265 actinium-225 PSMA, actinium supply agreements | Alpha-emitter combinations with existing oncology portfolio |
| Clarity Pharmaceuticals | ~0–1% | SAR-bisPSMA copper-64/copper-67 theranostic pair | Copper-based platform with centralized production advantages |

## Recent News & Developments

## Recent News & Developments

Several developments between 2023 and 2025 reshaped competitive positions in the Radioligand Therapy (RLT) Market.

- Eli Lilly and Company (December 2023): Completed the USD 1.4 billion acquisition of POINT Biopharma, gaining Lu-177 PSMA assets and Indianapolis manufacturing capacity [10]
- Bristol Myers Squibb (February 2024): Closed its USD 4.1 billion acquisition of RayzeBio, adding the actinium-225 SSTR agent RYZ101 and a dedicated production facility [8]
- U.S. FDA (April 2024): Approved Lutathera for patients aged 12 and older with SSTR-positive GEP-NETs, the first radioligand approved for pediatric use
- Novartis (May 2024): Agreed to acquire Mariana Oncology for USD 1 billion upfront, adding actinium-225 programs including a small cell lung cancer candidate [11]
- AstraZeneca (June 2024): Completed its acquisition of Fusion Pharmaceuticals, securing FPI-2265 and actinium-225 supply relationships
- Sanofi (September 2024): Licensed AlphaMedix, a lead-212 SSTR therapy, from RadioMedix and Orano Med, marking its entry into alpha emitters [20]
- ITM Isotope Technologies Munich SE (January 2025): Reported positive topline Phase 3 COMPETE results for ITM-11 versus everolimus in GEP-NETs [21]
- U.S. FDA (March 2025): Expanded Pluvicto's label to taxane-naïve PSMA-positive mCRPC, opening an earlier treatment line

## Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | The Radioligand Therapy (RLT) Market covers approved and late-stage radioligand drugs by target, indication and end user, delivered through cancer centers, nuclear medicine centers, hospitals and clinics. |
| Study Period | 2021–2035 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2035 |
| Market Size in 2025 | USD 5.29 Billion |
| Market Size in 2035 | USD 14.94 Billion |
| CAGR (2026–2035) | 10.94% |
| Fastest Growing Segments | Fibroblast Activation Protein (19.8% CAGR); Gastroenteropancreatic Neuroendocrine Tumors (17.3% CAGR); Breast Cancer (16.1% CAGR); Specialized Nuclear Medicine Centers (13.5% CAGR) |
| Regions Covered | North America, Europe, South America, Asia Pacific, Middle East and Africa and ROW |
| Companies Profiled | Novartis AG, Bayer AG, Lantheus Holdings, Curium, Telix Pharmaceuticals, ITM Isotope Technologies Munich SE, Bristol Myers Squibb, Eli Lilly and Company, AstraZeneca, Clarity Pharmaceuticals |
| Valuation Currency | USD Billion |
| Methodology | 350+ primary expert interviews; bottom-up market sizing; top-down validation; data triangulation; scenario-based forecasting; real-time project tracking |

## Frequently Asked Questions

**Q: How do beta-emitting and alpha-emitting payloads differ for buyers in the Radioligand Therapy (RLT) Market?**
A: Alpha emitters such as actinium-225 deliver far higher linear energy transfer over a path of only a few cell diameters, which can overcome resistance to Lu-177 agents. Their constraint is supply, since the DOE Isotope Program still produces actinium-225 in limited batches [17].

**Q: What infrastructure does a hospital need before administering radioligand treatments?**
A: Sites need an NRC or Agreement State license under 10 CFR Part 35, an authorized user physician, shielded storage and a waste decay program [14]. Most centers entering the Radioligand Therapy (RLT) Market also add a PSMA or SSTR PET pathway to select eligible patients.

**Q: How does companion imaging shape procurement in the Radioligand Therapy (RLT) Market?**
A: Buyers increasingly negotiate imaging and therapy agents together, because a positive PSMA or SSTR PET scan gates eligibility. Kit-based gallium-68 agents suit sites without a cyclotron, while fluorine-18 agents favor high-volume centers with regional cyclotron supply [15].

**Q: What do investors scrutinize in radiopharmaceutical deals?**
A: Diligence now centers on isotope access as much as clinical data, because a molecule without secured actinium-225 or Lu-177 supply cannot scale. Acquirers also value owned cyclotron or reactor partnerships, since contract capacity for GMP radiolabeling remains scarce [16].

**Q: Which regulatory designations can shorten timelines in the Radioligand Therapy (RLT) Market?**
A: FDA Breakthrough Therapy and Fast Track designations allow rolling submissions and more frequent agency meetings for qualifying radioligands. In China, the NMPA's conditional approval pathway lets sponsors file on surrogate endpoints, with confirmatory data required after launch [25].

**Q: How do short isotope half-lives affect patient scheduling?**
A: Lu-177 doses decay by roughly 10% per day, so manufacturers ship them for a fixed infusion slot and a missed appointment usually wastes the dose. Treatment centers in the Radioligand Therapy (RLT) Market therefore invest in scheduling software and dedicated radiopharmacy coordinators [16].

**Q: Can patients receive radioligand treatment without an overnight stay?**
A: In the United States, most patients go home the same day because NRC release criteria cap exposure to others at 5 millisieverts [14]. Several European countries apply stricter dose-rate limits, which still require short inpatient stays in shielded wards.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/radioligand-therapy-rlt-market-11824*